Microbot Medical filings document formal disclosures tied to the LIBERTY Endovascular Robotic System and the company’s commercial-stage medical-device operations. Recent Form 8-K reports furnish Regulation FD press releases on U.S. market release activity, healthcare-system adoption, procedure use, medical-society occupational-protection guidelines, and publication of the ACCESS-PVI pivotal study.
The filings also record Item 8.01 other-event disclosures and capital-markets matters, including an at-the-market common stock program under a shelf registration statement. These records describe the company’s Nasdaq-listed common stock, product commercialization, clinical-evidence communications, commercial organization updates, and related exhibit filings.
Microbot Medical Inc. filed an 8-K to report that the U.S. Food and Drug Administration has granted 510(k) clearance for its LIBERTY® Endovascular Robotic System, described as the first FDA-cleared single-use, remotely operated robotic system for peripheral endovascular procedures. This clearance allows the company to move ahead with final commercial activities that depended on marketing clearance and to begin U.S. commercialization, with an aim to address approximately 2.5 million annual U.S. peripheral vascular procedures and later pursue global markets. The company also disclosed that its President, CEO and Chairman, Harel Gadot, is presenting at the H.C. Wainwright Annual Investor Conference in New York on September 9, 2025, with a live webcast available via its website.
Microbot Medical Inc. reported that from August 26 to August 27, 2025 it issued 4,055,870 new shares of common stock through the exercise of previously issued preferred investment options. Holders exercised 300,000 Series H options at $2.10 per share and 3,755,870 Series I options at $2.13 per share, providing the company with approximately $8.6 million in gross cash proceeds before fees and expenses. As of August 27, 2025, Microbot Medical had about 52,569,762 common shares outstanding. The company relied on a private offering exemption under Section 4(a)(2), while the shares underlying both the Series H and Series I options had already been registered for resale on prior Form S-3 registration statements.
Microbot Medical Inc. reported unregistered sales of its common stock tied to option exercises. From August 11 to August 25, 2025, the company issued an aggregate of 2,967,953 shares of common stock upon the exercise of outstanding Series E, Series G, and Series H preferred investment options at exercise prices of $1.50, $1.75, and $2.10 per share, respectively, generating approximately $5.9 million in gross proceeds before fees and expenses. Microbot also issued 47,218 shares of common stock upon the exercise of incentive options by a former director. As of August 25, 2025, the company had approximately 48,513,892 shares of common stock issued and outstanding. The shares were issued as private transactions under Section 4(a)(2) of the Securities Act, and the shares underlying the preferred investment options had been previously registered for resale on Form S-3 registration statements.
Microbot Medical Inc. reported that the U.S. Patent and Trademark Office has granted it a patent covering a modular robotic surgical system with a base and multiple independently attachable tool-receiver units. The company explains that this patent may allow its LIBERTY device to be adapted over time for a wider range of endovascular procedures, which could substantially increase the total addressable market it seeks to reach. The patent also broadens Microbot’s intellectual property protection for the LIBERTY system portfolio, which now consists of 12 patents granted globally and 57 patent applications pending.
Microbot Medical Inc. discloses that three reporting persons — Mitchell P. Kopin, Daniel B. Asher and Intracoastal Capital LLC — may be deemed to beneficially own 4,200,951 shares of common stock, representing 9.99% of the class. That total consists of 7,700 shares held directly by Intracoastal and two warrants exercisable into 2,349,488 and 1,843,763 shares, respectively, which together create the reported position and corresponding shared voting and dispositive power.
The filing also discloses several warrant blocker provisions that exclude additional potential shares from the reported total: certain warrants cannot be exercised to the extent they would push ownership above 9.99% or 4.99%. The filing states that without those blocker provisions the reporting persons could be deemed to beneficially own 7,695,600 shares. The signatories certify the holdings were not acquired to change or influence control of the issuer.
Microbot Medical, Inc. is a pre-commercial, clinical-stage medical device company developing the LIBERTY® Endovascular Robotic Surgical System. As of June 30, 2025, the company held approximately $4.1 million in cash and $28.6 million in money market mutual funds (marketable securities), totaling about $32.7 million of cash and marketable securities and $33.1 million in total assets. Shareholders' equity rose to $30.4 million from $3.5 million at year-end 2024, primarily driven by equity financings completed in early 2025.
Microbot reported a net loss of $3.5 million for the quarter and $6.1 million for the six months ended June 30, 2025 (basic and diluted loss per share of $0.10 and $0.18, respectively). Operating cash used was $5.4 million for the six months, while financing activities provided $32.6 million of cash. The company remains pre-revenue, has an accumulated deficit of $97.0 million, notes continuing risks from Israeli regional instability, and states management believes available funds plus recent capital raises are sufficient to fund operations for more than twelve months from issuance of these statements.
Microbot Medical Inc. (Nasdaq: MBOT) filed a Form S-8 on 21 Jul 2025 to register an additional 3,791,019 common shares for issuance under its 2020 Omnibus Performance Award Plan. The pool was last expanded by 2,591,019 shares approved on 10 Jun 2025. The filing is made under General Instruction E and incorporates the company’s prior S-8 (File No. 333-250963).
The registration statement also includes a re-offer prospectus for up to 2,009,697 shares underlying options held by directors and officers that may be resold on a continuous basis under Rule 415. No proceeds will accrue to the company; any sales will be effected by the holders. With 39,991,652 shares outstanding, the newly registered shares equal roughly 9.5% potential dilution, while the re-offer covers about 5.0% of current float.
Corporate updates inside the prospectus note key milestones: 510(k) submitted for the fully disposable LIBERTY® Endovascular Robotic System (10 Dec 2024) with FDA clearance targeted for Q3 2025 and U.S. launch immediately thereafter; ISO 13485 certification obtained Aug 2024; CE-Mark expected 2H 2026. A $4.82 m ATM program (4.28 m shares) has been completed, and management states that ongoing regional conflicts have not yet produced material operational effects.